Key Developments: Digirad Corp (DRAD.W)

DRAD.W on CBOE When Trading NASDAQ Global Select Market

2.35USD
22 May 2013
Price Change (% chg)

$-0.05 (-2.08%)
Prev Close
$2.40
Open
$2.35
Day's High
$2.38
Day's Low
$2.35
Volume
300
Avg. Vol
41
52-wk High
$2.57
52-wk Low
$1.87

Search Stocks

Latest Key Developments (Source: Significant Developments)

Digirad Corp Increases Share Buyback
Wednesday, 13 Mar 2013 04:10pm EDT 

Digirad Corp announced that it has increased its share buyback program authorization to $12 million from the $7 million previously announced -- leaving approximately $10 million available in the plan, with a continued strong commitment to return value to shareholders.  Full Article

Digirad Corp Announces President Change-Form 8-K
Tuesday, 5 Mar 2013 10:03pm EST 

Digirad Corp reported in its Form 8-K that Board of Directors appointed Matthew G. Molchan, who has served as President, Digirad Imaging Solutions, Inc. since January 2012 to serve as President of Digirad Corporation, effective February 27, 2013. Todd P. Clyde, the Company’s current President and Chief Executive Officer (CEO), will continue to serve as Chief Executive Officer (CEO) during a transition period that is currently anticipated to end on July 1, 2013.  Full Article

Digirad Corp Announces Chairman Change-Form 8-K
Thursday, 7 Feb 2013 07:43am EST 

Digirad Corp reported in its Form 8-K that on February 6, 2013, Gerhard F. Burbach and R. King Nelson resigned from the Board of Directors (Board) of Digirad Corporation (Company). Jeffrey E. Eberwein has been appointed as the Chairman of the Board, replacing Mr. Nelson. John M. Climaco has been appointed to both the Audit Committee of the Board as well as the Compensation Committee of the Board.  Full Article

Digirad Corp Receives U.S. FDA 510(k) Market Clearance For Expanded Uses Of ergo(TM) Imaging System
Thursday, 31 Jan 2013 07:30am EST 

Digirad Corp announced that it has received U.S. FDA 510(k) market clearance to further expand the clinical flexibility of the ergo Imaging System for applications throughout the hospital, including the areas of nuclear medicine, surgery and women's health. The clearance includes indications for lymphatic scintigraphy and parathyroid scintigraphy, both nuclear diagnostic imaging tests, and to aid in the evaluation of lesions in the breast and other small body parts. The ergo can also be used intra-operatively when protected by sterile drapes. When used for breast imaging, the ergo System is indicated to serve as an adjunct to mammography or other primary breast imaging modalities.  Full Article

Digirad Corp Names Jeffry R. Keyes As CFO
Thursday, 6 Sep 2012 04:40pm EDT 

Digirad Corp announced that Jeffry R. Keyes has been named Chief Financial Officer (CFO), effective immediately. Keyes will report directly to Chief Executive Officer Todd P. Clyde.  Full Article

Digirad Corporation Announces Resignation Of Chief Financial Officer
Wednesday, 28 Mar 2012 04:00pm EDT 

Digirad Corporation announced that Richard B. Slansky has resigned his position as Chief Financial Officer(CFO) effective April 20, 2012, in order to accept another executive position. Digirad Chief Executive Officer Todd P. Clyde, who had formerly served as Digirad CFO for six years, will assume the CFO responsibilities on an interim basis until a new CFO is identified.  Full Article

Digirad Corporation And Dilon Diagnostics Enter Commercial Stage Of Technology Development And OEM Agreement
Monday, 6 Jun 2011 07:31am EDT 

Digirad Corporation and Dilon Diagnostics announced that Digirad has contributed advanced photodetector technology for use in Dilon's newest gamma camera, the FDA cleared Dilon 6800 Acella, via a technology development and OEM agreement. The introduction of the new Dilon imaging system marks the launch of commercial activities associated with the development agreement between the two companies that commenced in mid-2010.  Full Article

  • Previous
  • Next

Digirad Corp News

» More DRAD.W News

Earnings vs. Estimates

» More Financials
Search Stocks